vs

Side-by-side financial comparison of Mission Produce, Inc. (AVO) and BIOCRYST PHARMACEUTICALS INC (BCRX). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($406.6M vs $319.0M, roughly 1.3× Mission Produce, Inc.). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 5.0%, a 55.5% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs -10.0%). BIOCRYST PHARMACEUTICALS INC produced more free cash flow last quarter ($291.2M vs $55.6M). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs 11.0%).

Produce Co., Ltd. was a Japanese video game company. Founded on April 6, 1990 by former Irem employees, it developed a number of games for both Enix and Hudson Soft. Produce! have created games for arcades and for the Super Nintendo Entertainment System, Nintendo 64, PlayStation, and PC Engine systems.

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

AVO vs BCRX — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.3× larger
BCRX
$406.6M
$319.0M
AVO
Growing faster (revenue YoY)
BCRX
BCRX
+219.1% gap
BCRX
209.1%
-10.0%
AVO
Higher net margin
BCRX
BCRX
55.5% more per $
BCRX
60.5%
5.0%
AVO
More free cash flow
BCRX
BCRX
$235.6M more FCF
BCRX
$291.2M
$55.6M
AVO
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
11.0%
AVO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AVO
AVO
BCRX
BCRX
Revenue
$319.0M
$406.6M
Net Profit
$16.0M
$245.8M
Gross Margin
17.5%
97.7%
Operating Margin
8.8%
64.0%
Net Margin
5.0%
60.5%
Revenue YoY
-10.0%
209.1%
Net Profit YoY
-7.5%
1017.5%
EPS (diluted)
$0.23
$1.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVO
AVO
BCRX
BCRX
Q4 25
$319.0M
$406.6M
Q3 25
$357.7M
$159.4M
Q2 25
$380.3M
$163.4M
Q1 25
$334.2M
$145.5M
Q4 24
$354.4M
$131.5M
Q3 24
$324.0M
$117.1M
Q2 24
$297.6M
$109.3M
Q1 24
$258.7M
$92.8M
Net Profit
AVO
AVO
BCRX
BCRX
Q4 25
$16.0M
$245.8M
Q3 25
$14.7M
$12.9M
Q2 25
$3.1M
$5.1M
Q1 25
$3.9M
$32.0K
Q4 24
$17.3M
$-26.8M
Q3 24
$12.4M
$-14.0M
Q2 24
$7.0M
$-12.7M
Q1 24
$0
$-35.4M
Gross Margin
AVO
AVO
BCRX
BCRX
Q4 25
17.5%
97.7%
Q3 25
12.6%
98.6%
Q2 25
7.5%
98.3%
Q1 25
9.4%
96.9%
Q4 24
15.7%
95.4%
Q3 24
11.4%
97.3%
Q2 24
10.4%
98.4%
Q1 24
11.1%
98.6%
Operating Margin
AVO
AVO
BCRX
BCRX
Q4 25
8.8%
64.0%
Q3 25
5.9%
18.6%
Q2 25
1.8%
18.2%
Q1 25
2.8%
14.6%
Q4 24
8.1%
-3.4%
Q3 24
5.2%
6.6%
Q2 24
4.1%
8.0%
Q1 24
3.1%
-15.6%
Net Margin
AVO
AVO
BCRX
BCRX
Q4 25
5.0%
60.5%
Q3 25
4.1%
8.1%
Q2 25
0.8%
3.1%
Q1 25
1.2%
0.0%
Q4 24
4.9%
-20.4%
Q3 24
3.8%
-12.0%
Q2 24
2.4%
-11.6%
Q1 24
-38.1%
EPS (diluted)
AVO
AVO
BCRX
BCRX
Q4 25
$0.23
$1.13
Q3 25
$0.21
$0.06
Q2 25
$0.04
$0.02
Q1 25
$0.05
$0.00
Q4 24
$0.25
$-0.13
Q3 24
$0.17
$-0.07
Q2 24
$0.10
$-0.06
Q1 24
$0.00
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVO
AVO
BCRX
BCRX
Cash + ST InvestmentsLiquidity on hand
$64.8M
$274.7M
Total DebtLower is stronger
$95.8M
Stockholders' EquityBook value
$587.3M
$-119.2M
Total Assets
$983.0M
$514.2M
Debt / EquityLower = less leverage
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVO
AVO
BCRX
BCRX
Q4 25
$64.8M
$274.7M
Q3 25
$43.7M
$212.9M
Q2 25
$36.7M
$260.0M
Q1 25
$40.1M
$295.1M
Q4 24
$58.0M
$320.9M
Q3 24
$49.5M
$96.8M
Q2 24
$46.2M
$78.4M
Q1 24
$39.9M
$84.3M
Total Debt
AVO
AVO
BCRX
BCRX
Q4 25
$95.8M
Q3 25
$131.5M
Q2 25
$147.2M
Q1 25
$117.9M
Q4 24
$113.7M
Q3 24
$134.4M
Q2 24
$170.2M
Q1 24
$156.1M
Stockholders' Equity
AVO
AVO
BCRX
BCRX
Q4 25
$587.3M
$-119.2M
Q3 25
$568.7M
$-387.9M
Q2 25
$552.3M
$-421.6M
Q1 25
$550.8M
$-451.9M
Q4 24
$547.3M
$-475.9M
Q3 24
$527.3M
$-468.6M
Q2 24
$513.3M
$-475.6M
Q1 24
$505.1M
$-476.2M
Total Assets
AVO
AVO
BCRX
BCRX
Q4 25
$983.0M
$514.2M
Q3 25
$1.0B
$446.4M
Q2 25
$1.0B
$457.2M
Q1 25
$997.8M
$480.0M
Q4 24
$971.5M
$490.4M
Q3 24
$959.9M
$491.3M
Q2 24
$966.9M
$472.4M
Q1 24
$937.5M
$467.9M
Debt / Equity
AVO
AVO
BCRX
BCRX
Q4 25
0.16×
Q3 25
0.23×
Q2 25
0.27×
Q1 25
0.21×
Q4 24
0.21×
Q3 24
0.25×
Q2 24
0.33×
Q1 24
0.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVO
AVO
BCRX
BCRX
Operating Cash FlowLast quarter
$67.2M
$292.0M
Free Cash FlowOCF − Capex
$55.6M
$291.2M
FCF MarginFCF / Revenue
17.4%
71.6%
Capex IntensityCapex / Revenue
3.6%
0.2%
Cash ConversionOCF / Net Profit
4.20×
1.19×
TTM Free Cash FlowTrailing 4 quarters
$37.2M
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVO
AVO
BCRX
BCRX
Q4 25
$67.2M
$292.0M
Q3 25
$34.4M
$41.6M
Q2 25
$-11.8M
$41.3M
Q1 25
$-1.2M
$-27.5M
Q4 24
$38.0M
$-5.2M
Q3 24
$42.5M
$8.2M
Q2 24
$3.4M
$-1.4M
Q1 24
$9.5M
$-53.7M
Free Cash Flow
AVO
AVO
BCRX
BCRX
Q4 25
$55.6M
$291.2M
Q3 25
$22.6M
$40.3M
Q2 25
$-25.0M
$41.1M
Q1 25
$-16.0M
$-27.7M
Q4 24
$31.1M
$-5.9M
Q3 24
$34.9M
$8.2M
Q2 24
$-4.4M
$-1.5M
Q1 24
$-400.0K
$-53.9M
FCF Margin
AVO
AVO
BCRX
BCRX
Q4 25
17.4%
71.6%
Q3 25
6.3%
25.3%
Q2 25
-6.6%
25.2%
Q1 25
-4.8%
-19.0%
Q4 24
8.8%
-4.5%
Q3 24
10.8%
7.0%
Q2 24
-1.5%
-1.4%
Q1 24
-0.2%
-58.1%
Capex Intensity
AVO
AVO
BCRX
BCRX
Q4 25
3.6%
0.2%
Q3 25
3.3%
0.8%
Q2 25
3.5%
0.1%
Q1 25
4.4%
0.1%
Q4 24
1.9%
0.5%
Q3 24
2.3%
0.1%
Q2 24
2.6%
0.1%
Q1 24
3.8%
0.3%
Cash Conversion
AVO
AVO
BCRX
BCRX
Q4 25
4.20×
1.19×
Q3 25
2.34×
3.23×
Q2 25
-3.81×
8.12×
Q1 25
-0.31×
-859.91×
Q4 24
2.20×
Q3 24
3.43×
Q2 24
0.49×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AVO
AVO

Avocado$256.9M81%
Blueberry$36.5M11%
Mango$18.7M6%
Other$6.9M2%

BCRX
BCRX

Segment breakdown not available.

Related Comparisons